English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/93306
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes

AuthorsHernández, Cristina; García-Ramírez, Marta; González-Rodríguez, Águeda; Valverde, Ángela M.; Simó, Rafael
Issue Date2013
PublisherAmerican Diabetes Association
CitationDiabetes 62(7): 2569-2578 (2013)
AbstractRetinal neurodegeneration is an early event in the pathogenesis of diabetic retinopathy (DR). Somatostatin (SST) is an endogenous neuroprotective peptide that is downregulated in the diabetic eye. The aim of the study was to test the usefulness of topical administration of SST in preventing retinal neurodegeneration. For this purpose, rats with streptozotocin-induced diabetes mellitus (STZ-DM) were treated with either SST eye drops or vehicle for 15 days. Nondiabetic rats treated with vehicle served as a control group. Functional abnormalities were assessed by electroretinography (ERG), and neurodegeneration was assessed by measuring glial activation and the apoptotic rate. In addition, proapoptotic (FasL, Bid, and activation of caspase-8 and caspase-3) and survival signaling pathways (BclxL) were examined. Intraretinal concentrations of glutamate and its main transporter glutamate/aspartate transporter (GLAST) were also determined. Treatment with SST eye drops prevented ERG abnormalities, glial activation, apoptosis, and the misbalance between proapoptotic and survival signaling detected in STZ-DM rats. In addition, SST eye drops inhibited glutamate accumulation in the retina and GLAST downregulation induced by diabetes mellitus. We conclude that topical administration of SST has a potent effect in preventing retinal neurodegeneration induced by diabetes mellitus. In addition, our findings open up a new preventive pharmacological strategy targeted to early stages of DR. © 2013 by the American Diabetes Association.
DescriptionUnder License Creative Commons.-- et al.
Publisher version (URL)http://dx.doi.org/10.2337/db12-0926
URIhttp://hdl.handle.net/10261/93306
DOI10.2337/db12-0926
Identifiersdoi: 10.2337/db12-0926
issn: 0012-1797
e-issn: 1939-327X
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
Topical administration of somatostatin.pdf1,72 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.